We think that most investors do not appreciate how far along BSX might be in rectifying this problem in a timely manner, because a fix was in process at the time of the FDA inspections.
We think that most investors do not appreciate how far along BSX might be in rectifying this problem in a timely manner, because a fix was in process at the time of the FDA inspections.
We would expect BSX to quickly come back with a new bid, but importantly, we do not expect management to increase its debt or offer more equity.
© 2020 Inspirational Stories
© 2020 Inspirational Stories